Elvina Almuradova· @Dr_ElvinaA · X·· 12 小时前评分70
正文 · 原文
INTerpath-001: In macroscopic stage III melanoma, added value beyond neoadjuvant IO remains unclear. Next: target patients without MPR—but can vaccines overcome IO resistance? Value in stage IIB/IIC remains distinct.
#ESMO26 @Larvol @OncoAlert @myESMO
104 浏览 · 1 赞 · 2 转发 · 0 回复
会议摘要
LBA1按 Presidential Symposium I 对上
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgINTerpath-001
https://esmocongress.esmo.org来源：Elvina Almuradova · x.com